Cerevel Therapeutics Holdings, Inc.
(NASDAQ CM: CERE)
Rigrodsky Law, P.A. is investigating Cerevel Therapeutics Holdings, Inc. (“Cerevel”) regarding possible breaches of fiduciary duties and other violations of law related to Cerevel’s agreement to be acquired by AbbVie Inc. Under the terms of the agreement, Cerevel shareholders will receive $45.00 per share in cash.